JAMA NetworkUptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy

In this cohort study of 34,131 patients with cancer published in JAMA Oncology, trial ineligibility was associated with a greater likelihood of immune checkpoint inhibitor (ICI) monotherapy use compared with non-ICI therapy. Among trial-ineligible patients, there were no overall survival differences between treatment with ICI monotherapy, ICI combination therapy, and non-ICI therapy.